CTAD 2025
C2N Diagnostics, LLC, a leader in advanced brain health diagnostics, is adding to its evidence-based legacy at the Clinical Trials for Alzheimer’s Disease (CTAD) 2025 conference in San Diego December 1 – 4.
C2N continues to set a standard in innovation in Alzheimer’s disease diagnostics through numerous presentations by esteemed researchers and clinicians at CTAD. Join us in San Diego and be among the first to learn about exciting new data for the Precivity™ line of blood tests.
We encourage you to click this link to schedule a meeting with our team
All sessions and posters will be held at the Hilton Bayfront Hotel
11 sessions and 6 posters will offer novel insights relating to the Precivity™ blood tests. These presentations/posters include:
Sessions on C2N’s Test Data
Monday, December 1
4:20 PM
LB1 - Plasma Biomarkers To Identify and Predict Early Amyloid Accumulation in Cognitively Unimpaired Individuals: Enrichment for Stratified Early-Stage Prevention Trials
4:35 PM
LB2 - Anti-tau therapeutic antibody, etalanetug, reduces the novel biomarker plasma eMTBR tau243 in patients with DIAD**
4:50 PM
LB3 - Modulation of the p75 neurotrophin receptor in a phase 2a Alzheimer’s disease trial reduces plasma p-tau217, engages the synaptic proteome, and preserves visuospatial cognition
5:35 PM
Brainshuttle™ AD: New interim results of a randomized, placebo-controlled Phase Ib/IIa proof-of-concept study with trontinemab, a novel anti-amyloid monoclonal bispecific antibody for the treatment of Alzheimer’s disease
Tuesday, December 2
9:55 AM
OC3 - Biological staging of Alzheimer’s disease using blood-based biomarkers**
3:10 PM
Considerations in the Development and Use of Biomarkers for Combination Therapy in Alzheimer’s Disease
Wednesday, December 3
9:00 AM
LB17 - Multi-biomarker Plasma Clocks for Predicting Alzheimer Disease Symptom Onset
9:15 AM
LB18 - Longitudinal associations between Plasma p-tau217 and amyloid PET
9:55 AM
OC11 - Combining endogenous CSF MTBR-tau243 and plasma pTau217 enhances prediction of continuous regional tau PET burden in amyloid-positive early Alzheimer’s disease
2:25 PM
LB20 - Performance of blood-based Screening algorithm for Predicting AD Pathology and Baseline Characteristics of Participants in a Phase 2 trial of Etalanetug and Concurrent lecanemab.
Thursday, December 4
11:30 AM
Building a scalable and efficient recruitment funnel for preclinical Alzheimer’s disease: The AHEAD 3-45 model
Posters That Include C2N Data:
Wednesday, December 3
P192 The BEYONDD Study: Preliminary Plasma Biomarker Findings within a Community-Based Sample
P206 Diagnostic Performance of Multi-Analyte Algorithms and %p-tau217 using High Resolution LC-MS/ MS in a Mixed Memory Clinic Cohort
P211 Concordance of ApoE proteotype vs genotype assays: a low friction method for obtaining E4 carrier status
P215 A Comparative Analysis of Creatinine- and Cystatin C-based eGFR equations for the Assessment of Chronic Kidney Disease Influence on Plasma p-tau217 Concentrations
P256 C2N Eligibility, APOE genotype Identification, Amyloid Confirmation. Results from the AHEAD 3-45 program at Neuroclin Glasgow
Thursday, December 4
P357 Economic value of a blood test for Alzheimer’s disease pathology in primary and specialty care in the U.S.
** Work done at the laboratory of Dr Randall Bateman, Washington University, St Louis, MO
We look forward to seeing you in San Diego!
About C2N Diagnostics, LLC
C2N Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation™. C2N strives to provide exceptional laboratory services and products in the field of brain health. C2N’s biomarker services and products are used for: clinical decision making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. For more information visit www.C2N.com.